Immunoglobulin (Privigen) Therapy to Treat BK Viremia and Prevent Alloimmune Activation in Kidney Transplant Recipients

Trial Profile

Immunoglobulin (Privigen) Therapy to Treat BK Viremia and Prevent Alloimmune Activation in Kidney Transplant Recipients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Viraemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Apr 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 19 Apr 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top